NTAP provides additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. It goes into effect on Oct. 1, 2025. The company said the reimbursement win serves as an endorsement of its Minima system’s impact on patient outcomes.

Newport Beach, California-based Renata picked up FDA approval for the first-of-its-kind stent last fall. The company designed the stent to re-expand over the course of the child’s growth period. Minima’s growth technology supports aortic coarctation and pulmonary artery stenosis relief to re-expand as the patient grows. Delivered through the vein or artery in the groin or neck with a small needle, the device has a unique design. It features long, thin frames (struts), allowing crimping down to less than 2mm.